BRAF and chronic myelogenous leukemia, BCR-ABL1 positive: It is becoming clear that resistance to BRAF inhibitors will not follow the pathway of resistance of chronic myelogenous leukemia (CML) to imatinib, where secondary mutations in the abl kinase are the main mechanism of resistance [23].